Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15.06. | Upstream Bio: Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor | 3 | GlobeNewswire (USA) | ||
05.06. | Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 | 1 | GlobeNewswire (USA) | ||
20.05. | Upstream Bio Appoints Stacy Price As CTO | 1 | RTTNews | ||
20.05. | Upstream Bio names new chief technology officer | 1 | Investing.com | ||
20.05. | Upstream Bio Appoints Stacy Price as Chief Technology Officer | 92 | GlobeNewswire (Europe) | WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory... ► Artikel lesen | |
06.05. | Upstream Bio, Inc. reports Q1 results | 3 | Seeking Alpha | ||
06.05. | Upstream Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
06.05. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
01.04. | Pre-market Movers: Marblegate Acquisition Corp., iCoreConnect, Hyperscale Data, Upstream Bio, InnovAge Holding | 413 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green Marblegate Acquisition Corp. (GATE) is up over 55%... ► Artikel lesen | |
12.03. | Upstream Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
12.03. | Upstream Bio, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
12.03. | Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 142 | GlobeNewswire (Europe) | - Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 - - Completed upsized IPO... ► Artikel lesen | |
12.03. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
15.10.24 | Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | 183 | GlobeNewswire (Europe) | WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on... ► Artikel lesen | |
14.10.24 | HBM Healthcare Investments AG: Erfolgreicher Börsengang des HBM-Portfoliounternehmens Upstream Bio; Kapitalaufnahme von USD 255 Millionen | 897 | EQS Group (DE) | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
Erfolgreicher Börsengang des HBM-Portfoliounternehmens Upstream Bio; Kapitalaufnahme von USD 255 Millionen
14.10.2024... ► Artikel lesen | |
11.10.24 | Upstream Bio Prices Upsized IPO Of 15 Mln Shares At $17.00/shr | 1.026 | AFX News | WASHINGTON (dpa-AFX) - Upstream Bio Inc. (UPB) announced the pricing of its upsized initial public offering of 15 million shares of its common stock at a public offering price of $17.00 per... ► Artikel lesen | |
11.10.24 | Upstream Bio Announces Pricing of Upsized Initial Public Offering | 192 | GlobeNewswire (Europe) | WALTHAM, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Evotec Aktie mit Verkaufssignal: Konter oder Sturz auf 5 Euro? | Die Evotec Aktie hat am Donnerstag ein charttechnisches Verkaufssignal ausgelöst. Mit einem XETRA-Schlusskurs von 6,568 Euro fiel der Kurs um mehr als vier Prozent und unterschritt dabei mehrere relevante... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | -0,71 % | CARGO Therapeutics, Inc. - 8-K, Current Report | ||
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |